RT Journal Article
SR Electronic
T1 The kinetic of SARS-CoV-2 antibody (Ab) decline determines the threshold for Ab persistence up to one year
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.09.20.21263172
DO 10.1101/2021.09.20.21263172
A1 Garner-Spitzer, Erika
A1 Wagner, Angelika
A1 Kundi, Michael
A1 Stockinger, Hannes
A1 Repic, Anna
A1 Schoetta, Anna-Margarita
A1 Gudipati, Venugopal
A1 Huppa, Johannes B.
A1 Kunert, Renate
A1 Mayrhofer, Patrick
A1 Kreil, Thomas R.
A1 Farcet, Maria R.
A1 Hoeltl, Eva
A1 Wiedermann, Ursula
YR 2021
UL http://medrxiv.org/content/early/2021/09/27/2021.09.20.21263172.abstract
AB Twelve subjects with positive SARS-CoV-2 neutralization test (NT) titers (>1:10) identified in a seroprevalence study with 1655 working adults were followed up for one year. Here we report that 7 of these 12 individuals (58%) still had NT titers ≥1:50, S1-specific IgG concentrations ≥50 BAU/ml and ≥26% ACE2 receptor binding inhibition, measured with surrogate virus NT one year after mild COVID infection. Furthermore, NT_50 titers >1:10 and S1-specific IgG levels >60 BAU/ml present at three months post-infection persisted at detectable levels for 1 year and correlated with circulating S1-specific memory B-cells. Vaccine-induced SARS-CoV2 immune responses decline at similar rates as those after infection; thus the describes threshold of 60 BAU/ml at three months post infection might also be relevant for assessment of Ab persistence after vaccination.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialThe ethics committee of the Medical University of Vienna approved this monocentric study (EK 1438/2020, EK 1746/2020).Funding StatementThe study received funding from the Austrian Federal Ministry of Education, Science and Research within the research framework in relation to the coronavirus disease 2019 pandemic (GZ 20200225 104).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The ethics committee of the Medical University of Vienna approved this monocentric study (EK 1438/2020, EK 1746/2020).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAfter publication deidentified participant data will be available to researchers, whose proposed use of the data has been approved by the corresponding author.